Epetraborole
Phase 3Small molecule
Epetraborole is one of 27 small molecule programs targeting Lung Disease. It is currently in Phase 3.
1
Indications
5
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Lung Disease
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Colcrys
Jazz PharmaceuticalsApproved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Duragesic
CCephalon
Approved
Viagra
VViatris Specialty LLC
Approved
Esbriet
LLegacy Health System
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Inomax
MMallinckrodt
Approved
Ketalar
AAultman Health Foundation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lung Disease2 trials
Adult Subject1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epetraborole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAN2 Therapeutics, Inc